Anthrax vaccine adsorbed

Anthrax vaccine adsorbed, sold under the brand name Biothrax among others, is a vaccine intended to provide acquired immunity against Bacillus anthracis.

This article is about the US-licensed vaccine product. For the US government program, see Anthrax Vaccine Immunization Program.

Anthrax vaccine adsorbed
Vaccine description
TargetBacillus anthracis
Vaccine typeSubunit
Clinical data
Trade namesBiothrax, Cyfendus
Other namesrPA102
AHFS/Drugs.comMonograph
MedlinePlusa607013
License data
Routes of
administration		Subcutaneous, intramuscular
ATC code
Legal status
Legal status
  • CA: ℞-only
  • US: ℞-only
Identifiers
DrugBank
ChemSpider
  • none
UNII
 NY (what is this?)  (verify)

Anthrax vaccine adsorbed originated in studies done in the 1950s and was first licensed for use in humans in 1970. In the US, the principal purchasers of the vaccine are the Department of Defense and Department of Health and Human Services. Ten million courses (60 million doses) of the vaccine have been purchased for the US Strategic National Stockpile in anticipation of the need for mass vaccinations owing to a future bio-terrorist anthrax attack. The product has attracted some controversy owing to alleged adverse events and questions as to whether it is effective against the inhalational form of anthrax.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.